A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Eligibility Criteria

• * Has a confirmed advanced (unresectable and/or metastatic) solid tumor
• * Has measurable disease by RECIST 1.1 as assessed by the local site investigator/radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions
• * Has archival tumor tissue sample or newly obtained biopsy of a tumor lesion not previously irradiated has been provided
• * Who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible
• * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
• * Hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization.
• * Who has history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
• * Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 3 days before intervention allocation/randomization
• * Has adequate organ function
• * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)
• * Has uncontrolled significant cardiovascular disease or cerebrovascular disease
• * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing
• * Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
• * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
• * Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the start of study intervention
• * Has received prior radiotherapy within 2 weeks of start of study intervention
• * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
• * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
• * Has active infection requiring systemic therapy
• * Has concurrent active Hepatitis B (defined as hepatitis B surface antigen (HBsAg) positive and/or detectable HBV deoxyribonucleic acid (DNA) and Hepatitis C virus (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA) infection